This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olinger, G. G.
Right arrow Articles by Hart, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olinger, G. G.
Right arrow Articles by Hart, M. K.

 Previous Article  |  Next Article 

Journal of Virology, November 2005, p. 14189-14196, Vol. 79, No. 22
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.22.14189-14196.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Protective Cytotoxic T-Cell Responses Induced by Venezuelan Equine Encephalitis Virus Replicons Expressing Ebola Virus Proteins

Gene G. Olinger, Michael A. Bailey, John M. Dye, Russell Bakken, Ana Kuehne, John Kondig, Julie Wilson, Robert J. Hogan, and Mary Kate Hart*

United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, Maryland

Received 11 January 2005/ Accepted 15 August 2005

Infection with Ebola virus causes a severe disease accompanied by high mortality rates, and there are no licensed vaccines or therapies available for human use. Filovirus vaccine research efforts still need to determine the roles of humoral and cell-mediated immune responses in protection from Ebola virus infection. Previous studies indicated that exposure to Ebola virus proteins expressed from packaged Venezuelan equine encephalitis virus replicons elicited protective immunity in mice and that antibody-mediated protection could only be demonstrated after vaccination against the glycoprotein. In this study, the murine CD8+ T-cell responses to six Ebola virus proteins were examined. CD8+ T cells specific for Ebola virus glycoprotein, nucleoprotein, and viral proteins (VP24, VP30, VP35, and VP40) were identified by intracellular cytokine assays using splenocytes from vaccinated mice. The cells were expanded by restimulation with peptides and demonstrated cytolytic activity. Adoptive transfer of the CD8+ cytotoxic T cells protected filovirus naïve mice from challenge with Ebola virus. These data support a role for CD8+ cytotoxic T cells as part of a protective mechanism induced by vaccination against six Ebola virus proteins and provide additional evidence that cytotoxic T-cell responses can contribute to protection from filovirus infections.

* Corresponding author. Mailing address: United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702-5011. Phone: (301) 619-4917. Fax: (301) 619-2290. E-mail: marykate.hart{at}amedd.army.mil.

Journal of Virology, November 2005, p. 14189-14196, Vol. 79, No. 22
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.22.14189-14196.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Halfmann, P., Ebihara, H., Marzi, A., Hatta, Y., Watanabe, S., Suresh, M., Neumann, G., Feldmann, H., Kawaoka, Y. (2009). Replication-Deficient Ebolavirus as a Vaccine Candidate. J. Virol. 83: 3810-3815 [Abstract] [Full Text]  
  • Bradfute, S. B., Warfield, K. L., Bavari, S. (2008). Functional CD8+ T Cell Responses in Lethal Ebola Virus Infection. J. Immunol. 180: 4058-4066 [Abstract] [Full Text]  
  • Dowling, W., Thompson, E., Badger, C., Mellquist, J. L., Garrison, A. R., Smith, J. M., Paragas, J., Hogan, R. J., Schmaljohn, C. (2007). Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines. J. Virol. 81: 1821-1837 [Abstract] [Full Text]  
  • Martin, J. E., Sullivan, N. J., Enama, M. E., Gordon, I. J., Roederer, M., Koup, R. A., Bailer, R. T., Chakrabarti, B. K., Bailey, M. A., Gomez, P. L., Andrews, C. A., Moodie, Z., Gu, L., Stein, J. A., Nabel, G. J., Graham, B. S., the VRC 204 Study Team, (2006). A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. CVI 13: 1267-1277 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»